Development of predictive indicators and treatment strategies for dementia associated with diabetes and obesity focusing TREM2 and monocyte function
Description: The triggering receptor expressed on myeloid cells 2 (TREM2) is a transmembrane protein mainly expressed on macrophages and microglia, and involved in inflammation. In this study, serum levels of soluble TREM2 (sTREM2) significantly correlated with the decrease of MMSE, a test of cognitive function, in the patients with diabetic enrolled in a National Hospital Organization multicenter study. In the general population of the Hisayama study, incidences of dementia elevated significantly with higher serum sTREM2 levels. These findings suggested that serum sTREM2 levels may be useful to estimate the risk of dementia in clinical practice. Furthermore, we demonstrated that using mice model of dementia, the flavonoid taxifolin, which has strong antioxidant effects, significantly suppress TREM2 expression in hippocampus and amyloid-beta production, resulting in improvement of cognitive function. Accordingly, TREM2 could be an index for predictor and indicator of drug efficacy for dementia.
Amount: ¥17,420,000
Funding type: research
Funder scheme: Grant-in-Aid for Scientific Research (B)
Start date: 2018-04-01
End date: 2021-03-31
Investigator: Noriko Satoh-Asahara (lead)
Institutions: Kyoto Medical Center, Department of Clinical Research, National Hospital Organization Kyoto Medical Center
Subfield: Neurology
Field: Neuroscience
Domain: Life Sciences
Funded outputs count: 46
Funder award ID: 18H02737
OpenAlex ID: G2629871682
